MDGH Invests in PCI Pharma Services
Why we think this is neutral
The RNS announcement does not contain any of the mandatory news types, such as contract news, order news, trading update, financing, funding, annual results, asset sale, flow testing, licensing, or delisting. Therefore, the sentiment is neutral.
Key Points
- MDGH subsidiary to reinvest into PCI Pharma Services
- PCI Pharma Services is a global contract development and manufacturing organization focused on biotherapies
- Transaction subject to customary closing conditions and regulatory approvals
Summary
The diversified holding company has announced an investment into a global contract development and manufacturing organization focused on biotherapies.
MDGH, a diversified global holding company, has announced that one of its wholly-owned subsidiaries has entered into an agreement to reinvest into PCI Pharma Services, a world-leading global contract development and manufacturing organization focused on innovative biotherapies. The completion of the transaction is subject to customary closing conditions and regulatory approvals.
GENERAL UPDATE